## nature research

|--|

Last updated by author(s): Jan 10, 2021

## **Reporting Summary**

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

| ~        |     |     | 0.00 |        |
|----------|-----|-----|------|--------|
| <u>_</u> | ta: | tic | :†:  | $\sim$ |
|          |     |     |      |        |

| AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)   | For | JII ST | atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.   |
|--|-----|--------|---|
| Image: Problem in the statistical statistical parameters were taken from distinct samples or whether the same sample was measured repeatedly in the statistical test(s) used AND whether they are one- or two-sided in the Methods section.         Image: Problem in the statistical test(s) used AND whether they are one- or two-sided in the Methods section.         Image: Only common tests should be described solely by name; describe more complex techniques in the Methods section.         Image: Image: Problem in the Methods section in the Methods section.         Image: I | n/a | Cor    | nfirmed   |
| The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.  A description of all covariates tested  A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)  For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.  For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated  |     | X      | The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement   |
| Only common tests should be described solely by name; describe more complex techniques in the Methods section.  A description of all covariates tested  A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)  For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.  For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated  |     | x      | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly   |
| A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)  For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.  For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated  |     | ×      | The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.  |
| A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)  For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.  For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated   | X   |        | A description of all covariates tested  |
| AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)  For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.  For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated  | x   |        | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons   |
| Give P values as exact values whenever suitable.  For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated   |     | ×      | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated   |     | ×      | For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>                       |
| Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated   | X   |        | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |
|  | X   |        | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |
| Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.  | x   |        | Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated  |
|  |     |        | Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.   |

## Software and code

Policy information about <u>availability of computer code</u>

No specialized software was used for data collection.

As per the Methods, the ImageJ distribution Fiji was used for image analysis, including measurement of endothelial permeability, tumor cell extravasation, arrest, and migration. The software OriginPro was used for statistical analysis.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

## Data

Data analysis

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The datasets generated during the current study are available from the corresponding authors on reasonable request. All data underlying the graphs presented in the main figures is available as Supplementary Data.

| Fiold spe  | ecific reporting  |  |  |  |  |
|--|---|--|--|--|--|
|  | <u> </u>  |  |  |  |  |
| Life sciences  | ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.  Behavioural & social sciences  |  |  |  |  |
| For a reference copy of  | the document with all sections, see <a href="mailto:nature.com/documents/nr-reporting-summary-flat.pdf">nature.com/documents/nr-reporting-summary-flat.pdf</a>  |  |  |  |  |
|  |   |  |  |  |  |
| Life scier   | nces study design   |  |  |  |  |
| All studies must dis   | sclose on these points even when the disclosure is negative.  |  |  |  |  |
| Sample size  | Sample size was chosen based on previous studies by us and others on the use of microfluidic models for assessment of biological phenomena. As demonstrated by the single data points in each figure, the sample size chosen described well the variability in the measurements.  |  |  |  |  |
| Data exclusions  | For the tumor cell extravasation assay, regions of interest that contained clumps of tumor cells rather than single cells were removed due to abnormally high extravasation efficiency.   |  |  |  |  |
| Replication  | The permeability and tumor extravasation values measured are comparable to those reported by us in the past.  |  |  |  |  |
| Randomization  | Not applicable to this study.   |  |  |  |  |
| Blinding   | Blinding was performed when comparing the cell lines SN12C and SN12PM6. For these cells, arrest and extravasation efficiencies, and CD44 and HA expressions were each measured by the first author without knowledge of the cell line.  |  |  |  |  |
|  |   |  |  |  |  |
| Danastin   | a for an acific masterials, evetomas and mastered   |  |  |  |  |
|  | g for specific materials, systems and methods   |  |  |  |  |
|  | on from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, ted is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.   |  |  |  |  |
| Materials & ex   | perimental systems Methods  |  |  |  |  |
| n/a Involved in th   | ne study n/a Involved in the study  |  |  |  |  |
| Antibodies   |   |  |  |  |  |
| Eukaryotic   |   |  |  |  |  |
| -1-  | Palaeontology and archaeology   MRI-based neuroimaging  |  |  |  |  |
| X Animals and other organisms  |   |  |  |  |  |
|  |   |  |  |  |  |
| Clinical data   Dual use research of concern                                   |   |  |  |  |  |
| Dual use research of Concern   |   |  |  |  |  |
| Antibodies   |   |  |  |  |  |
| Antibodies used  | As per the Methods, the antibodies used were against E-selectin (BBA16, R&D Systems), P-selectin (701257, ThermoFisher), VCAM-1 (AB134047, Abcam), ICAM-1 (MA5407, ThermoFisher), CD44 (GTX102111, GeneTex), CD31 (ab32457, Abcam), β-actin (926-42210, Li-Cor), ICAM-1 (62133S, Cell Signaling Technologies), ZO-1 (33-9100, ThermoFisher), and HS (370255, Amsbio). |  |  |  |  |
| Validation   | All antibodies were validated by the manufacturers as described on their web pages.   |  |  |  |  |
|  | · · ·   |  |  |  |  |
| Eukaryotic c   | ell lines   |  |  |  |  |
| Policy information about <u>cell lines</u>                                     |   |  |  |  |  |
| Cell line source(s)  | source(s) MDA-MB-231 and MCF7 cell lines were obtained from ATCC. SN12C and SN12PM6 cells were obtained from the MD Anderson Characterized Core Facility.   |  |  |  |  |
| Authentication Authentication of the cell lines was performed by the suppliers |   |  |  |  |  |

All cell lines in our laboratory tested negative to mycoplasma contamination during periodic testing.

None of the lines used in this study are present in the ICLAC register.

Mycoplasma contamination

Commonly misidentified lines (See <u>ICLAC</u> register)